«

»

Inflation Reduction Act will restrict oncology drug development, Bristol-Myers Squibb CEO says

With tighter rules from the Inflation Reduction Act approaching, Bristol-Myers Squibb will cancel plans for some drug development programs and cancer treatments, the drugmaker's CEO, Giovanni Caforio, MD, recently told the Financial Times. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive